(-0.09%) 5 303.50 points
(0.01%) 40 149 points
(-0.15%) 18 476 points
(1.63%) $82.68
(1.40%) $1.742
(0.73%) $2 228.80
(0.24%) $24.81
(0.77%) $916.70
(0.26%) $0.926
(0.51%) $10.82
(0.01%) $0.791
(-0.14%) $92.31
Live Chart Being Loaded With Signals
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity...
Stats | |
---|---|
Today's Volume | 115 316 |
Average Volume | 255 324 |
Market Cap | 74.52M |
EPS | $0 ( 2024-03-20 ) |
Next earnings date | ( $-0.450 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.640 |
ATR14 | $0.00800 (0.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-21 | Olek Elizabeth A | Sell | 7 368 | Common Stock |
2024-02-16 | Olek Elizabeth A | Sell | 0 | Common Stock |
2024-02-16 | Olek Elizabeth A | Sell | 89 120 | Stock Option (Right to Buy) |
2024-02-16 | Olek Elizabeth A | Sell | 145 795 | Stock Option (Right to Buy) |
2024-02-16 | Olek Elizabeth A | Sell | 87 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
46.62 |
Last 97 transactions |
Buy: 7 377 688 | Sell: 1 665 671 |
Volume Correlation
Kronos Bio, Inc. Correlation
10 Most Positive Correlations | |
---|---|
VVOS | 0.892 |
PASG | 0.886 |
SRTS | 0.876 |
SGBX | 0.876 |
FREQ | 0.863 |
ATHE | 0.858 |
CNDT | 0.852 |
FOSL | 0.846 |
KOD | 0.841 |
VNET | 0.84 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kronos Bio, Inc. Correlation - Currency/Commodity
Kronos Bio, Inc. Financials
Annual | 2023 |
Revenue: | $6.29M |
Gross Profit: | $1.37M (21.82 %) |
EPS: | $-1.950 |
Q4 | 2023 |
Revenue: | $2.29M |
Gross Profit: | $1.81M (79.09 %) |
EPS: | $-0.430 |
Q3 | 2023 |
Revenue: | $917 000 |
Gross Profit: | $407 000 (44.38 %) |
EPS: | $-0.540 |
Q2 | 2023 |
Revenue: | $1.86M |
Gross Profit: | $685 000 (36.75 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators